5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The T-Cell Lymphoma Market is segmented by Type of Lymphoma, Type of Therapy (Radiotherapy, Chemotherapy, Others), and Geography.
Fastest Growing Market:
Lymphoma is the most common blood cancer. It occurs when cells of the immune system, called lymphocytes (a type of white blood cells), grow and multiply uncontrollably in the human body. Certain factors that are driving the market growth include a rise in lymphoma cancer incidence due to radiations, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders. Cancerous lymphocytes can affect body parts, including the lymph node, spleen, bone marrow, blood, or other organs, and can form a mass called a tumor. The increase in cancer drug prices, in the last 15 years, has been a problem for the global population. Patients who have developed cancer may not be able to afford treatment, due to the high costs associated with it. Due to the high cost of treatment, it is very difficult for everyone to afford cancer therapies or drugs, which limits the market.
T-cell lymphoma is a type of cancer, which forms in T cells (a type of immune system cell). T-cell lymphomas may either be indolent (slow-growing) or be aggressive (fast-growing). Most of the T-cell lymphomas are non-Hodgkin lymphomas. There are also many different types of T-cell non-Hodgkin lymphomas, such as mycosis fungoides, anaplastic large cell lymphoma, and precursor T-lymphoblastic lymphoma. The prognosis and treatment depend on the type and stage of cancer.
|By Type of Lymphoma|
|Peripheral T-cell Lymphoma|
|Cutaneous T-cell Lymphoma|
|Anaplastic Large Cell Lymphoma|
|Angio-immuno-blastic T-cell Lymphoma|
|Other Types of Lymphoma|
|By Type of Therapy|
Report scope can be customized per your requirements. Click here.
Lymphomas are generally classified as Hodgkin lymphoma and non-hodgkin lymphoma, depending on the types of cells. T-cell lymphomas are non-Hodgkin lymphomas that develop from T lymphocytes. According to the American Cancer Society, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States that accounts for about 4% of all cancers. There are a variety of treatment options available for the treatment of T-cell lymphoma and leukemia. While surgery and radiation therapy are used to remove or kill cancer cells in a particular area, chemotherapy can act on the rapidly dividing cancer cells throughout the entire body. With intensive chemotherapy, the complete remission rate can be very high, and many patients can be cured. Chemotherapy for the treatment of T-cell lymphoma or leukemia may be delivered in several ways, such as intravenous, oral, and intrathecal. Hence, owing to these factors, the market is expected to witness significant growth in the future years.
To understand key trends, Download Sample Report
According to the Lymphoma Research Foundation, T-cell lymphomas account for about 7% of all non-Hodgkin's lymphoma (NHL) in the United States, according to their Surveillance, Epidemiology, and End Results program. In addition, Angioimmunoblastic T-Cell Lymphoma (AITL) is a rare, aggressive type, accounting for about 7-8% of all patients having T-cell lymphomas in the United States. Most patients have been found to be middle-aged to elderly, and are diagnosed with advanced-stage disease. Several organizations are currently playing a significant role in spreading awareness regarding T-cell Lymphoma across the region. For example, the Leukemia and Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research, education and patient services. . Furthermore, due to these rising incidences in the United States, the T-cell lymphoma market is expected to grow during the forecast period.
To understand geography trends, Download Sample Report.
The market is highly competitive and consists of a few major players. Companies, like Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Genmab A/S, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis, F. Hoffmann-La Roche Ltd, Autolus Therapeutics plc, and Spectrum Pharmaceuticals, among others, hold the substantial market share in the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Lymphoma Cancer Incidence
4.2.2 Increase in Number of T-cell Lymphoma Specific Therapies
4.2.3 Risk of Lymphoma due to Autoimmune Disorders
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Adverse Side Effects of Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Lymphoma
5.1.1 Peripheral T-cell Lymphoma
5.1.2 Cutaneous T-cell Lymphoma
5.1.3 Anaplastic Large Cell Lymphoma
5.1.4 Angio-immuno-blastic T-cell Lymphoma
5.1.5 Other Types of Lymphoma
5.2 By Type of Therapy
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocryst Pharmaceuticals Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Genmab A/S
6.1.4 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
6.1.5 Merck & Co. Inc.
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Novartis International AG
6.1.8 Autolus Therapeutics plc
6.1.9 Spectrum Pharmaceuticals
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments